breast cancer - HR positive | |
la/mBC - HR positive | |
pembrolizumab based treatment | |
pembrolizumab alone | NCT03051659 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -